Products are for research use only. Not for human use. We do not sell to patients. Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively

ChemLeader Biomedical Co.,Limited was founded in 2010, is a professional research chemical supplier specializing in R&D, manufacturing and sales. The headquarters is located in Shanghai International Medical Zone(SIMZ), Pudong New District, Shanghai, China, with over 30000 square feet sales office/ research laboratory and 20000 square feet pilot plant. Our branches in Xuzhou, Shandong, and Hong Kong.

We are committed to provide the highest quality products and the best service to pharmaceutical company and scientific research institutions in China and international markets. Our team has had extensive expertise and an excellent background in synthetic chemistry, project management, CRO, QC/QA, pilot plant etc.

As an innovation-driven and customer-focused company, we also specialize in custom synthesis of organic compounds, various drug intermediates as well as a variety of specialty and fine chemicals ranging from milligram to tons scale.

With our whole Professional team's efforts for many years we gain the admiration and trust from the domestic and overseas clients, and favorable position and Reputation in China Pharmaceutical and Fine Chemicals field. We are devoted to decreasing the production cost, optimizing the artwork, creating and keeping the accomplishment of best environmental, health, and safety performance in the industry.